Exosome Diagnostics said this week that Cedars-Sinai Medical Center will be an early-access user of the company's exosome RNA biofluid extraction kits for biomarker discovery in neo-natal and other disease settings.

Cedars-Sinai will access the kit through Exosome's "center of excellence" program, which is designed to allow clinical centers already performing research on blood-based biomarkers in exosomes to use Exosome's EXO50 exosome isolation and extraction technology ahead of commercial launch.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.